A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy and safety of Albuferon in combination
with ribavirin in interferon (IFN) alfa treatment-naïve subjects with chronic hepatitis C
genotype 1. The study will randomize subjects to 1 of 4 treatment groups including 3
different Albuferon groups or to the active control group, peginterferon alfa-2a (PEGASYS,
PEG-IFNalfa-2a). All subjects will also receive oral daily ribavirin.